Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
Trial Parameters
Brief Summary
This is a Phase Ib/II study to assess the safety, tolerability and preliminary efficacy of AK119 combined with AK112 in patients with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria: 1. Voluntarily written informed consent and agree to comply with all protocol-specified procedures and follow-up evaluations 2. Age ≥ 18 years and ≤ 75 years 3. Histologically or cytologically-confirmed diagnosis of advanced/unresectable solid tumor that have been progressed or intolerant to at least one standard treatment regimen in the advanced or metastatic setting, if such a therapy exists 4. Measurable lesion based on RECIST v1.1 5. ECOG status of 0 or 1 6. Life expectancy ≥ 3 months 7. Adequate organ function 8. Women of childbearing potential and men with female partners of childbearing potential must agree to use effective contraception during treatment and for at least 120 days following the last dose of study treatment Exclusion Criteria: 1. Known other active malignancy within 3 years prior to the first dose of investigational product, with the exception of early stage cancers that have treated with curative intent 2. Currently participating in another st